InMode reported Q2 2026 GAAP revenues of $95.6 million, flat compared to Q2 2025, with margin compression evident in the earnings. The company's RF microneedling and radiofrequency platforms, once growth engines, are facing market saturation and competitive pressure.
Devices & Tech
InMode Q2 Flat Revenue, Margins Compress
Energy-device leader faces stagnation and pricing pressure as market matures and competition intensifies.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
InMode's flat revenue and margin compression signal market saturation and rising competitive pressure.
This is a warning signal for practices. InMode's installed base is mature; flat revenue suggests limited new unit placements and possible price competition from Cutera, Lumenis, and emerging ultrasound platforms like Sofwave. Margin compression typically precedes aggressive rebate or financing offers to move inventory. Practices with InMode equipment should monitor lease renewal terms closely—manufacturers often tighten rebates when top-line growth stalls. The flat revenue also reflects market consolidation: practices are consolidating device portfolios rather than adding new modalities, and InMode's premium pricing may be losing ground to lower-cost RF alternatives.
Source: original report ↗
Frequently asked questions
What does InMode's flat Q2 revenue mean for my practice's equipment costs?
Flat revenue ($95.6M in Q2 2026 vs. Q2 2025) signals margin pressure on InMode, which typically leads to aggressive rebates and financing offers to move inventory. This creates a buyer's market—practices should negotiate harder on lease renewals and equipment pricing before manufacturers lock in terms.
Is InMode losing market share to competitors?
Yes. InMode faces competition from Cutera, Lumenis, and emerging ultrasound platforms like Sofwave, with practices consolidating device portfolios rather than adding new units. The company's premium pricing is losing ground to lower-cost RF alternatives as the market matures.
Should I renew my InMode equipment lease now or wait?
Monitor renewal terms closely. Margin compression typically precedes tighter rebate structures, so negotiate aggressively now while manufacturers are incentivized to move units. Waiting risks facing worse terms once inventory pressure eases.
What's driving the RF microneedling market slowdown?
Market saturation and competitive intensity are compressing InMode's growth. Practices are consolidating equipment rather than expanding, and the installed base is mature with limited new unit placements, suggesting the RF category has peaked in adoption.
Which device manufacturers should I consider as InMode alternatives?
Cutera and Lumenis are direct RF competitors gaining share, while Sofwave represents an emerging ultrasound alternative. Evaluate lower-cost RF options and alternative modalities as practices shift away from premium-priced platforms during market consolidation.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.